Evidence map›Paper›PMID 41314952›Full record

ArticleCancer letters2026

Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990].

Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, Zhongyue Yang, Jiangnan Hu, Eden Demissie Alamaw, Lisa Zhang, Ya-Qin Zhang, Min Shen, Yasmine Tabdili and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Chandrayee GhoshDepartment of Surgery, Stanford University, Stanford, CA, USA. Electronic address: cghosh@stanford.edu.
Tejinder Pal KhaketDepartment of Surgery, Stanford University, Stanford, CA, USA.
Viswanath GundaDepartment of Surgery, Stanford University, Stanford, CA, USA.
Zhongyue YangDepartment of Surgery, Stanford University, Stanford, CA, USA.
Jiangnan HuDepartment of Surgery, Stanford University, Stanford, CA, USA.
Eden Demissie AlamawDepartment of Comparative Medicine, Veterinary Service Center, Stanford University, Stanford, CA, USA.
Lisa ZhangEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Ya-Qin ZhangNational Center for Advancing Translational Sciences, National Institute of Health, Bethesda, MD, USA.
Min ShenNational Center for Advancing Translational Sciences, National Institute of Health, Bethesda, MD, USA.
Yasmine TabdiliUniversity of Arizona, College of Medicine, Tucson, AZ, USA.
Myriem BoufraqechSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Rodas KassuDepartment of Surgery, Stanford University, Stanford, CA, USA.
Electron KebebewDepartment of Surgery, Stanford University, Stanford, CA, USA. Electronic address: kebebew@stanford.edu.

Funding

Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Intramural NIH HHS ZIA BC011286
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41314952
PMCPMC12817305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.